Drug interactions
Belzutifan + Brentuximab
Severity: Minor
Belzutifan and Brentuximab: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Belzutifan is a weak CYP3A4 inducer and could lower exposure to the CYP3A4-metabolized MMAE released from brentuximab vedotin. The reduction is expected to be small and its clinical significance for efficacy is uncertain.
What this interaction means in plain words
Belzutifan and Brentuximab have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Belzutifan belongs to Miscellaneous; Brentuximab belongs to Oncology.
Why it happens
Weak induction of CYP3A4 may increase metabolism of MMAE.
What to do
No dose change is generally needed. Monitor treatment response.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Belzutifan and Brentuximab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Brentuximab
- Bleomycin + Brentuximab Contraindicated
- Brentuximab + Dengue vaccine Major
- Brentuximab + Etrasimod Major
- Brentuximab + Idelalisib Major
- Brentuximab + Levoketoconazole Major
- Brentuximab + Nefazodone Major
Other interactions of Belzutifan
Frequently asked questions
Can I take Belzutifan with Brentuximab?
MediHelp rates the interaction as minor. Belzutifan and Brentuximab have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Belzutifan is a weak CYP3A4 inducer and could lower exposure to the CYP3A4-metabolized MMAE released from brentuximab vedotin. The reduction is expected to be small and its clinical significance for efficacy is uncertain.
How serious is the interaction between Belzutifan and Brentuximab?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose change is generally needed. Monitor treatment response.
What other medicines interact with Brentuximab?
MediHelp also lists interactions of Brentuximab with, for example, Bleomycin, Dengue vaccine, Etrasimod. The full list is on the Brentuximab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
